Treatment progress of BRAF V600E-mutated metastatic colorectal cancer
10.3760/cma.j.cn115355-20230419-00197
- VernacularTitle:BRAF V600E突变转移性结直肠癌治疗进展
- Author:
Weiwei PENG
1
;
Huanhuan SHA
;
Ying FANG
;
Zhiya WU
;
Guoren ZHOU
Author Information
1. 江苏省肿瘤医院肿瘤内科 江苏省肿瘤防治研究所 南京医科大学附属肿瘤医院，南京 210009
- Keywords:
Colorectal neoplasms;
BRAF V600E mutation;
Immunotherapy;
Molecular targeted therapy
- From:
Cancer Research and Clinic
2024;36(5):396-400
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is the most common malignant tumor of digestive tract, and BRAF V600E mutations occur in approximately 10% of patients with metastatic colorectal cancer (mCRC). Cancer patients harboring this mutation have a unique molecular profile and clinical phenotype; they show poor response to systemic chemotherapy, insensitivity to single BRAF inhibitor, and short survival rate. It is important to develop new therapeutic agents and clinical strategies to improve the prognosis of these patients. This review mainly introduces treatment methods for BRAF V600E-mutated mCRC and rationally derived combinations of targeted agents and immunotherapy.
